erlotinib hydrochloride has been researched along with Animal Mammary Carcinoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bode, A; Gill, SC; Grubbs, CJ; Iwata, KK; Juliana, MM; Lubet, RA; Nicastro, HL; Steele, VE; Szabo, E; Tucker, C | 1 |
| Bachawal, SV; Sylvester, PW; Wali, VB | 2 |
3 other study(ies) available for erlotinib hydrochloride and Animal Mammary Carcinoma
| Article | Year |
|---|---|
Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis.
Topics: Alkylating Agents; Animals; Blotting, Western; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Mammary Neoplasms, Animal; Methylnitrosourea; Phosphorylation; Quinazolines; Rats; Rats, Sprague-Dawley; Survival Rate; Tissue Distribution | 2013 |
Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromans; Culture Media, Serum-Free; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Mammary Neoplasms, Animal; Mice; Quinazolines; Signal Transduction; Trastuzumab; Vitamin E | 2010 |
Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Proliferation; Chromans; Erlotinib Hydrochloride; Female; Gefitinib; Mammary Neoplasms, Animal; Mice; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT Transcription Factors; Vitamin E | 2010 |